United Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 9.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,302 shares of the biotechnology company’s stock after selling 345 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in United Therapeutics were worth $1,185,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of UTHR. Geode Capital Management LLC boosted its position in United Therapeutics by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after purchasing an additional 45,566 shares during the last quarter. FMR LLC lifted its holdings in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after buying an additional 314,004 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock valued at $210,869,000 after buying an additional 30,931 shares in the last quarter. Janus Henderson Group PLC increased its holdings in United Therapeutics by 12.3% in the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock worth $164,978,000 after buying an additional 50,409 shares during the last quarter. Finally, Assetmark Inc. raised its position in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 121,864 shares of company stock worth $44,516,965 in the last ninety days. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Up 2.2 %

Shares of UTHR stock opened at $353.31 on Wednesday. United Therapeutics Co. has a 12 month low of $210.64 and a 12 month high of $417.82. The firm has a market cap of $15.78 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. The stock has a 50 day moving average of $362.06 and a 200-day moving average of $358.24.

Analysts Set New Price Targets

UTHR has been the subject of several recent research reports. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, LADENBURG THALM/SH SH raised their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $382.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.